[超声或闪烁扫描测定的甲状腺体积与格雷夫斯病治疗中放射性碘剂量计算的相关性及其意义]
[Correlation between thyroid volume determined either by ultrasound or by scintigraphy and its implications in dosimetric radioiodine calculations in Graves disease treatment].
作者信息
Vieira Lucas de Oliveira, Kubo Rodrigo, Sapienza Marcelo Tatit, Willegaignon José, Chammas Maria Cristina, Coura-Filho George Barberio, Ono Carla Rachel, Watanabe Tomoco, Sado Heitor Naoki, Buchpiguel Carlos Alberto
机构信息
Serviço de Medicina Nuclear, Instituto de Radiologia, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
出版信息
Arq Bras Endocrinol Metabol. 2011 Dec;55(9):696-700. doi: 10.1590/s0004-27302011000900005.
INTRODUCTION
Graves disease (GD) is the most common cause of hiperthyroidism, and the most common treatment options are surgery, antithyroid drugs and radioiodine therapy. In radiodosimetric calculations to determine radioiodine dosage it is possible to use thyroid volume estimatives based on ultrasound or scintigraphy.
OBJECTIVE
The present study aimed to correlate these methodologies emphasizing volume estimatives and dosimetric implications.
SUBJECTS AND METHODS
Were included 103 patients with GD diagnosis and indication of radioiodine treatment. They were submitted to thyroid ultrasound and thyroid scintigraphy.
RESULTS AND CONCLUSIONS
Good correlation between both methods was observed, although scintigraphy systematically obtained greater volumes than ultrasound implying in lower estimatives of absorbed dose when scintigraphy is used.
引言
格雷夫斯病（GD）是甲状腺功能亢进最常见的病因，最常见的治疗选择是手术、抗甲状腺药物和放射性碘治疗。在确定放射性碘剂量的放射剂量学计算中，可以使用基于超声或闪烁扫描的甲状腺体积估计值。
目的
本研究旨在关联这些方法，重点关注体积估计和剂量学影响。
对象与方法
纳入103例诊断为GD且有放射性碘治疗指征的患者。对他们进行甲状腺超声和甲状腺闪烁扫描。
结果与结论
观察到两种方法之间具有良好的相关性，尽管闪烁扫描系统地获得的体积比超声更大，这意味着使用闪烁扫描时吸收剂量的估计值较低。
Zotero 插件